EKB Journal Management System
Keywords = Daclatasvir
Number of Articles: 31
1

Evaluation of Patients' Recovery from Hepatitis C Following Antiviral Treatment with Daclatasvir and Sofosbuvir in AL-Baha Region

Volume 4, Issue 1, June 2024, Page 1-20
Fahad Salem Mushref Alghamdi; Rashed Mohammed
2

Association of multiple mutations in NS5A and NS5B genes and resistance to direct-acting antivirals in chronically infected Egyptian patients with Hepatitis C virus Genotype 4a

Volume 8, Issue 1, January and February 2024, Page 2320-2338
Gehad M. Mohamed; Ahmed B. Barakat; Marwa M. Gado; Fatma M. Abdallah
3

Impact of Treatment of Chronic HCV Patients by Direct Acting Antiviral Drugs (DAADs) on COVID -19 Disease Frequency and Severity

Volume 13, Issue 4, December 2023, Page 225-239
Rasha H Shehata; Eman A Zareh; Ehab F Moustafa; Mariam Elkhyat; Nahed A Makhlof
4

Association of Serum Interlukin-6 and Transforming Growth Factor Beta with Response to Antiviral Therapy for Chronic Hepatitis C Patients

Volume 32, Issue 4, October 2023, Page 61-69
Hayam H.M. Mahmoud; Salwa S.A. Seif Eldin; Sahar M. Nour; Aliaa M. Ghandour
5

Efficacy and Safety of Generic (Velpatasvir containing regimen) among Adult Chronic HCV Patients Non-responders to Treatment by Sofosbuvir Plus Daclatasvir Regimen in Egypt

Volume 46, Issue 3, June 2023, Page 11-24
Eman M. Fares1; Wessam M. Ragab; Heba A. Eldash; Naglaa R. Ismael; Ahmed A. Gomaa
6

SHORT AND LONG TERM CARDIOTOXICITY OF SOFOSBUVIR AND DACLATASVIR ASSOCIATED WITH LIPID PROFILE ABNORMALITIES

Volume 46, Issue 1, June 2023, Page 551-563
Sherin Zakaria; Shady Allam; Alaa E. El-Sisi
7

EVALUATION OF THE SAFETY AND RESISTANCE ASSOCIATED VARIANTS OF SOFOSBUVIR/DACLATASVIR AMONG EGYPTIAN PATIENTS WITH HEPATITIS C VIRUS: A PROSPECTIVE STUDY

Volume 45, Issue 2, December 2022, Page 1143-1153
Haidi Karam -Allah Ramadan; , Soha Saoud Abdel-Monem; Ahlam Mohamed Ahmed; Rasha Maree Omar; Hala Rady Ahmed; Helal F. Hetta
8

The effect of OCT-2 inhibitor Daclatasvir on Metformin pharmacokinetics and pharmacodynamics at two dose levels: A Bayesian approach using Markov-Chain Monte Carlo simulations

Volume 6, Issue 2, December 2022, Page 238-252
Mohamed Raslan; Lamia Elwakeel; Sara Shahin
9

Evaluation of Macular and Choroidal Thickness by Optical Coherence Tomography with Direct Acting Antiviral Agents in Patients with Chronic Hepatitis C Virus Infection

Volume 89, Issue 1, October 2022, Page 4881-4886
Doaa Saad Yusuf; Abdelrahman Gaber Salman; Tarek M. Yosef; Walid Mohamed Elzawahry; Walaa M. Hashem
10

Age and Gender are Predictors for Occult Hepatitis C in Egyptian Sustained Responders to Directly Acting Antivirals

Volume 89, Issue 1, October 2022, Page 4552-4557
Tarek Yosef; Maha M. Hussein; Amr Elzohary; Tari M.A. George Michael
11

Combined Sofosbuvir/Daclatasvir and Chemotherapy Markedly Improve The Outcome of B-Lymphoid Malignancies in Patients with Both HCV Infection and B-Lymphoid Malignancy

Volume 89, Issue 1, October 2022, Page 4676-4684
walaa gamal soliman; Amr Mohamed Zaghloul; Ali Mohammed Ali; Mohamed Soliman Gaber
12

The Possible Histological Effects of Daclatasvir on Liver Cells of the Pregnant Mice

Volume 45, Issue 3, September 2022, Page 687-702
Mennat Allah Saqr; Hoda Saleib; Nader Elnemr; Hoda Mahmoud Khalifa; Nancy El Sekily
13

Safety and Efficacy of Sofosbuvir Based Regimens in the Treatment of HCV Recurrence Post Liver Transplantation

Volume 87, Issue 1, April 2022, Page 973-978
Mohamed Abbasy; Mohamed Ahmed Afifi; Eman Abd El-Sameea Mahmoud; Tary Abd El-Hamid Salman; Eman Ahmed Rewisha; OmKolsoum Mohamed Al Haddad; Talaat Zakareya Ibrahim
14

Safety and Efficacy of Direct Acting Antivirals for Hepatitis C Virus Infection in Thalassemic Patients and Its Effect on Transfusion Requirements

Volume 87, Issue 1, April 2022, Page 1975-1981
Gina Gamal Naguib; Maha Abd El-Aziz Eltouny; Ossama Ashraf Ahmed; Iman Ahmed Ragab; Shereen Abdel-Monem Ibrahim; Sherif Ahmed Megahed Ahmed; Walaa M. Hashem
15

Development and Validation of HPLC Method for Quantification of Daclatasvir in Pure and Solid Dosage Form

Volume 65, Issue 2, February 2022, Page 81-91
Nida Saeed; Muhammad Shaharyar Khan Afridi; Abida Latif; Hafiz Hanzalah Fahham; Itzaz Aslam; Muhammad Mazhar; Muhammad Shahbaz Khan Afridi
16

Safety & Efficacy of Direct Acting Antiviral (Sofosbuvir & Daclatasvir) in Treatment of Chronic HCV in HIV-HCV Co-Infected Egyptian Patients

Volume 7, Issue 1, January 2022, Page 37-43
M.A. Mohamed; M.M. Elbadry; H.S. Alegaily
17

Assessment of Patient Compliance during treatment of chronic hepatitis C infection using Sofosbuvir and Daclatasvir with or without Ribavirin.

Volume 5.2, Issue 2, March 2021, Page 32-39
Sarah Ali; Farag Mohamed; Maha R Habeeb
18

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients

Volume 3, Issue 1, January 2021, Page 1053-1059
Mohamed G. Mohamed; Mohamed B. Bastawy; Mostafa A. Elhawary; Mohamed R. Rashed
19

Safety and Efficacy of Direct Acting Antivirals (Sofosbuvir & Daclatasvir) in treatment of Chronic HCV in HIV-HCV Co-Infected Egyptian Patients

Volume 81, Issue 4, October 2020, Page 1750-1753
Mahmoud Ezat Hegazy; Ihab Barsoum Fahim; Mahmoud Ahmed Sharaf Eldin; Saeed Abd Elbaky Gad
20

Health-related quality of life in Egyptian patients with chronic hepatitis C before and after treatment with direct acting antivirals

Volume 26, Issue 5, September 2020, Page 877-882
asmaa haroun nosair; waleed ismail; Emad F Hamed; Ghada Mohammed Salem
21

Efficacy of Sofosbuvir-Daclatasvir in Treatment of Chronic Hepatitis C Virus Infection

Volume 5, Issue 6 part (2), September 2020, Page 241-251
Y.S. Younis; T.E. Elazab; E.M. Abd El-Fattah
22

Efficacy of Sofosbuvir and Ledipasvir in Comparison to Sofosbuvir and Daclatasvir in Management of Egyptian Chronic Hepatitis C Patients

Volume 10, Issue 2, June 2020, Page 163-173
Israa Alaa Nouh; Adila Mostafa; Eman Elsheimy; Sameh Sief; Basem Eysa
23

Biochemical Hepatic Changes in Chronic Hepatitis C Patients Induced by Sofosbuvir and Daclatasvir with or without Ribavirin Regimens

Volume 29, Issue 2, April 2020, Page 137-144
Rashed M. Hasen; Nagla Abd Al Monem; Kamal A. Amer; Manal M. El-Gerby
24

Pulmonary complications of antiviral drugs (Sofosbuvir and Daclatasvir) used in treatment of patients with chronic hepatitis C virus

Volume 1, Issue 3, March 2020, Page 314-318
Eid Mohammed Mahmoud Mohammed; Ibrahim Abd-Elfattah Mohsen; Talaat Abd-Elaziz Arafa; Diaa Mohammed Elteiby
25

Study of Interferon-γ-Inducible Protein 10 (IP 10) Level as a Diagnostic and Prognostic Marker in Patients on Sofosbuvir and Daclatasvir as Antiviral Therapy of Chronic Hepatitis C.

Volume 77, Issue 4, October 2019, Page 5434-5441
Mostafa Yousef ELmishad; Alsayed Ahmed Gouda; Ali Saad Elden Nada; Ahmed Hussin Al-Dehna
First Page Previous Page 1 2 Next Page Last Page